The application of SilverHawk atherectomy device in the treatment of femoropopliteal occlusive disease
10.3969/j.issn.1006-5725.2017.18.020
- VernacularTitle:SilverHawk斑块切除系统在股腘动脉硬化闭塞性疾病中的应用
- Author:
Likun SUN
1
;
Bing WANG
;
Junchao LIU
;
Xiaoyang NIU
;
Xiaozhe LIU
;
Mengyu WANG
;
Jinxuan PAN
Author Information
1. 郑州大学第五附属医院血管外科
- Keywords:
lower extremity;
arteriosclerosis obliteran;
atherectomy;
femoral artery;
popliteal artery
- From:
The Journal of Practical Medicine
2017;33(18):3060-3063
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the safety and efficacy of SilverHawk directional atherectomy device in the treatment of femoropopliteal occlusive disease. Methods From August 2012 to June 2014,46 patients(58 limbs)with femoropopliteal occlusive diseases in the treatment by SilverHawk directional atherectomy device were analyzed retrospectively . The mean lesion length and degree of diameter stenosisin the femoropopliteal stenoses(52 limbs) were (4.6 ± 2.3) cm and (85.6 ± 11.3)％.The mean lesion length in the femoropopliteal occlusions(6 limbs)was(6.3 ± 3.2)cm. Rutherford score was 3 ～ 5. Mean ABI was 0.45 ± 0.36. Patency was evaluated with color duplex sonography,CTA and DSA postoperatively. Results 46 patients(58 limbs)were recanalizated suc-cessfully via intraluminal approach. The overall technical success rate was 100％. The procedural success rate was 93.10％. Postoperative residual stenosis and ABI were(10.3 ± 6.2)％and 1.05 ± 0.32,which had statistical diff erence compared with preoperative(t=5.83,P=0.02). The average period of follow-up was 22 months. Mean ABI during the follow-up was 0.96 ± 0.15,which had statistical difference compared with preoperative(t = 5.09,P =0.03). The 6-month and 1-and 2-year primary patency rate was 94.83％、91.38％、84.48％,and secondary patency rate was 98.28％、96.55％、93.10％,respectively. Conclusion SilverHawk directional atherectomy device is safe and effective in treament offemoropopliteal occlusive disease ,with satisfactory early-middle results.
